The global ANCA vasculitis drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). ANCA vasculitis is an autoimmune disease that affects the body's tiny blood vessels. Autoantibodies known as ANCAs, or Anti-Neutrophilic Cytoplasmic Autoantibodies, cause it. Neutrophils are a type of white blood cell that ANCAs target and attack. They go after the cytoplasm, which is a portion of neutrophils (the inside of the cell.) When autoantibodies (ANCAs) bind to neutrophils, the neutrophils target the body's tiny blood vessels. This is how vasculitis (blood vessel inflammation) occurs in this condition. As a result of ANCAs, neutrophils (a type of white blood cell) assault small blood arteries, causing them to swell and inflame. These ANCAs are not found in the majority of persons (autoantibodies that attack small blood vessels). Anti-B lymphocyte stimulatory monoclonal antibody belimumab is being tested in clinical studies for the treatment of ANCA-associated vasculitis GPA. Mepolizumab and Omalizumab are biologics that have been shown to be effective in the treatment of refractory asthma caused by EGPA.

The ANCA vasculitis drugs market has shown significant growth in recent years owing to the new product launches by the market players. Some major key players in the market include Novartis International AG, and GlaxoSmithKline plc, among others. These market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2020, AVISE Vasculitis AAV, a new testing panel of individual analytes designed to provide physicians with rapid and reliable results in the assessment and monitoring of ANCA-associated vasculitis, was launched by Exagen Inc. an organisation dedicated to transforming the care continuum for patients suffering from autoimmune diseases (AAV).

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Application

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Novartis International AG, and GlaxoSmithKline plc, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global ANCA Vasculitis Drug Market Report by Segment

By Type 

• Belimumab
• Dalazatide 
• CCX-168
• Others 

By Application 

• Clinic
• Hospital
• Others

Global ANCA Vasculitis Drug Market Report by Region

• North America
• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa